CT-P6, a Trastuzumab Biosimilar, Shares the Safety and Efficacy Profile of Its Reference
June 8th 2017Research presented at the 2017 Annual Meeting of the American Society of Clinical Oncology (ASCO) shows that CT-P6, a proposed trastuzumab biosimilar, is safe and effective as a neoadjuvant treatment in HER2–positive early breast cancer.
Analysis of Physicians' Notes Shows Slow Uptake for Filgrastim-sndz
June 1st 2017In a study presented at the 22nd Annual International Meeting of The International Society for Pharmacoeconomics and Outcomes Research, researchers sought to identify physicians’ documented granulocyte colony-stimulating factor (G-CSF) use, with a particular focus on filgrastim-sndz since its entry into the marketplace, and identified a slow US uptake for the biosimilar.